JAMA 282:1344–1352PubMedCrossRef 2. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91PubMedCrossRef 3. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340PubMedCrossRef 4. Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese
MA et al (2002) The efficacy Selleckchem Verteporfin and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. selleck chemicals Calcif Tissue Int 71:103–111PubMedCrossRef 5. Delmas PD, Benhamou CL, Man Z, Tlustochowicz W, Matzkin E, Eusebio R et al (2008) Monthly dosing of 75-mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporos Int 19:1039–1045PubMedCrossRef 6. Delmas PD, McClung MR, Zanchetta JR, Racewicz A, Roux
C, Benhamou CL et al (2008) Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36–42PubMedCrossRef 7. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137–1148PubMedCrossRef 8. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D et al (2000) Therapeutic equivalence of alendronate 70-mg once-weekly and alendronate 10-mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1–12 9. Miller PD, C-X-C chemokine receptor type 7 (CXCR-7) McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B et al (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20:1315–1322PubMedCrossRef 10. EMEA (2008) Evaluation
of new medicinal products in the treatment of primary osteoporosis [homepage on the Internet]. European Medicines Agency, Committee for Medicinal Products for Human Use, London, England; c1995-2010 [updated 2008 Nov 25; cited 2010 Jan 25]. At: http://www.ema.europa.eu/pdfs/human/ewp/55295enfin.pdf Funding for this study and writing/editorial support were provided by Warner Chilcott Pharmaceuticals and Sanofi.”
“Introduction Mechanical loading is the principal functional determinant of bone mass and architecture [1–3], and numerous studies have shown that prostaglandin signalling plays a key role in mechanotransduction, with cyclooxygenase-2 (COX-2) expression being rapidly up-regulated in both osteoblasts and osteocytes following exposure to fluid flow or mechanical strain in vitro [4–6]. Blocking prostaglandin production with MLN8237 in vitro indomethacin in experimental animals in vivo has repeatedly been shown to impair the osteogenic response to a single period of mechanical loading in cortical and trabecular bone [7–9].